The additive prognostic value of lipoprotein(a) for all-cause and cardiovascular mortality across the traditional cardiovascular risk continuum: analysis from NHANES III (1988–1994) with follow-up to 2019

Elevated Lp(a) levels (> 75 mg/dL) are associated with increased all-cause and CV mortality among individuals with high baseline traditional CV risk, as defined by the AHA's PREVENT score, independent of traditional risk factors. Our findings highlight the value of Lp(a) particularly among those with elevated baseline risk, where its prognostic utility appears greatest.